A Phase 2 interventional study of HTX-011 and Bupivacaine HCl in Analgesia, sponsored by Heron Therapeutics. Withdrawn. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Heron Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing bupivacaine in Hernia, Inguinal — 1 open to participants now, 2 under way, none of them phase 3. Bupivacaine · Hernia, Inguinal.
Among the 19 studies testing bupivacaine in Hernia, Inguinal, this one is the 19th largest by enrollment, is one of 2 that started in 2023, is one of 3 in phase 2, and was the 10th registered.
545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.
Browse Hernia, Inguinal studies →1 of the 19 studies testing bupivacaine in Hernia, Inguinal is open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Ages 18–75
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 3 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2004; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 70 across the 19 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 19 have an industry lead sponsor. The 10 most frequent:
Heron Therapeutics is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 12 (86%) have results posted.
Heron Therapeutics has 5 studies filed under Hernia, Inguinal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing bupivacaine in Hernia, Inguinal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 study in pediatric subjects undergoing inguinal herniorrhaphy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition to the preceding exclusion criteria 1 through 14, subjects to be enrolled in Cohort 1 Part B, Cohort 2 Part B, or Cohort 3 who meet any of the following criteria prior to randomization will be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adolescents ≥12 to \<17 years of age. A single dose of HTX-011 via instillation into the surgical site.
Drug: HTX-011 · Device: Luer Lock Applicator
Adolescents ≥12 to \<17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site.
Drug: Bupivacaine HCl
Adolescents ≥12 to \<17 years of age. Dose to be determined from Cohort 1 Part A.
Drug: HTX-011 · Device: Luer Lock Applicator
Adolescents ≥12 to \<17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
Drug: Bupivacaine HCl
Children ≥6 to \<12 years of age. Dose to be determined from Cohort 1.
Drug: HTX-011 · Device: Luer Lock Applicator
Children ≥6 to \<12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
Drug: Bupivacaine HCl
Children ≥6 to \<12 years of age. Dose to be determined from Cohort 1.
Drug: HTX-011 · Device: Luer Lock Applicator
Children ≥6 to \<12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
Drug: Bupivacaine HCl
Children ≥3 to \<6 years of age. Dose to be determined from Cohorts 1 and 2.
Drug: HTX-011 · Device: Luer Lock Applicator
Children ≥3 to \<6 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
Drug: Bupivacaine HCl
Drug pages: Bupivacaine · Meloxicam
Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
Drug pages: Bupivacaine · Meloxicam
Dose to be determined from Cohort 1.
Drug pages: Bupivacaine · Meloxicam
Dose to be determined from Cohorts 1 and 2.
Drug pages: Bupivacaine · Meloxicam
Dose to be determined from Cohort 1 Part A.
Applicator for instillation.
Area under the concentration-time curve (AUC) from Time 0 extrapolated to infinity (AUCinf)
Time frame: 72 hours
Maximum concentration (Cmax)
Time frame: 72 hours
Time of occurrence of maximum concentration (Tmax)
Time frame: 72 hours
Adolescents ≥12 to <17 years of age (Cohort 1): area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A)
Time frame: 72 hours
Children ≥6 to <12 years of age (Cohort 2): AUC of the Faces-Pain-Scale (FPS)-Revised pain intensity scores
Time frame: 72 hours
Children ≥3 to <6 years of age (Cohort 3): AUC of the Faces, Legs, Activity, Cry, Consolability (FLACC) scale pain intensity scores
Time frame: 72 hours
Total postoperative opioid consumption (in IV morphine milligram equivalents)
Time frame: 72 hours
Proportion of subjects who are opioid-free
Time frame: 72 hours
AUC of the Numeric Rating Scale pain intensity scores at rest (NRS-R)
Time frame: 72 hours
Proportion of subjects who do not receive an opioid prescription at discharge.
Time frame: 72 hours
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2023; primary completion for Nov 2025, 28 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bupivacaine · Meloxicam